Table 4 Predictors of BET score = 1 in the first year of treatment
From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
OR | CI | P | OR | CI | P | |
Sex (female vs male) | 1.18 | 0.38–3.70 | 0.78 | - | - | - |
Age | 1.02 | 0.96–1.09 | 0.46 | - | - | - |
Disease duration | 0.98 | 0.89–1.07 | 0.63 | - | - | - |
ARR in the pre-treatment year | 1.69 | 1.04–2.75 | 0.03 | 1.69 | 1.04–2.75 | 0.03 |
EDSS gain the pre-treatment year | n.a. ‡ | n.a. | n.a. | n.a. | n.a. | n.a. |
EDSS at baseline | 0.91 | 0.67–1.25 | 0.58 | - | - | - |
EDSS at baseline, categorized | 0.19 | - | - | - | ||
3.0 to 3.5 compared to < = 2.5 | 2.00 | 0.46–8.78 | 0.36 | - | - | - |
4.0 to 5.5 compared to < = 2.5 | 3.00 | 0.62–14.62 | 0.17 | - | - | - |
6 and above compared to < = 2.5 | 0.50 | 0.09–2.64 | 0.41 | - | - | - |
High pre-treatment disease activity | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |